Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental gene therapy hopes to slow rare brain disease in toddlers

NCT ID NCT04998396

First seen Apr 25, 2026 · Last updated May 19, 2026 · Updated 4 times

Summary

This study tests a gene therapy called BBP-812 in children up to 30 months old with Canavan disease, a rare and severe brain disorder. The treatment uses a harmless virus to deliver a working copy of the ASPA gene, aiming to reduce harmful brain chemicals and improve motor and thinking skills. The main goals are to check safety and measure changes in brain chemistry over one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANAVAN DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND)

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCSF Benioff Children's Hospital Oakland

    RECRUITING

    Oakland, California, 94609, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Weill Cornell Medicine; Division of Pediatric Neurology

    COMPLETED

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.